Gilead Sciences

Executive Summary

Gilead Sciences is a global biopharmaceutical leader with a strong legacy in virology, particularly HIV and hepatitis, and a growing presence in oncology. The company's robust pipeline includes next-generation antiretroviral therapies, such as the long-acting HIV drug lenacapavir, and innovative oncology assets like Trodelvy. Gilead's strategy focuses on areas of high unmet medical need, leveraging its expertise in small molecules and biologics. With a market cap exceeding $170B and a diversified portfolio, Gilead is well-positioned for sustained growth. Recent approvals and positive clinical data across key programs underscore the company's ability to innovate and execute. Key drivers include expansion of its HIV franchise, progress in cell therapy, and pipeline advancements in inflammatory diseases.

Upcoming Catalysts (preview)

• 2026 Q3Lenacapavir Expanded Approval for HIV Prevention80% success
• 2026 Q4Trodelvy Label Expansion in Bladder Cancer Phase 3 Data70% success
• 2026 Q3Phase 2 Readout for Yescarta in Lupus Nephritis60% success